Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults. - Wikidata - wikimedia - TriplyDB

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

http://www.wikidata.org/entity/Q34085125

about

Safety and efficacy profile of lenvatinib in cancer therapy: a systematic review and meta-analysis Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer Lenvatinib: first global approval.Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma.The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.Pharmacodynamic and Pharmacokinetic Markers For Anti-angiogenic Cancer Therapy: Implications for Dosing and Selection of Patients.Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor.Managing Drug Interactions in Cancer Therapy: A Guide for the Advanced Practitioner

P2860

Q33433315-FEF0AE3F-2B07-4965-B90D-1893ECA5326D Q35741930-A734061F-329E-4A5C-A5F1-3890768F9D65 Q36825455-B2CB4855-404A-4E60-A496-B4E8FB5D0934 Q36924717-DBA162C3-8934-46B4-B073-E0BCB770B534 Q38385844-F98D1B17-2F5D-49FE-8B0B-CA284F798867 Q39011379-2A47AB7C-E21E-479A-9538-E14A0DD76B57 Q39442851-0438F5DE-24CE-4043-B7CB-C83E280D2034 Q45930783-3452CA8F-725B-45B6-A7A2-AB816779F3AA Q50091855-12092CB0-977B-4134-988F-DDC918C3BF34 Q53520555-E4901B2E-ABF4-46B0-9B85-8BEA8ADC9A50 Q57498748-EC8D7FD9-765D-49D8-933E-D7BA4135F8E4

P2860

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

http://www.wikidata.org/entity/Q34085125

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@ast

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@en

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@nl

type

label

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@ast

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@en

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@nl

prefLabel

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@ast

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@en

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@nl

P1433

Q34085125-538A0CF4-CCE5-4AF5-84A0-4A260EAA6D9C

P1476

Q34085125-6A4B8D75-6779-49CB-A0DB-532FCA61C6D7

P2093

Q34085125-1F363BE9-E9BE-4F83-BCB2-B6250DEF4700

Q34085125-34C7907E-EA7A-463E-851A-DAC27F187C6B

Q34085125-8DA004E5-112D-441E-BEC8-965803E34D96

Q34085125-9ABBF6B0-10D4-4AD6-8650-E92F75C2A9C6

Q34085125-B3CDC6AF-5902-4E84-9785-3ED9F0A6569D

Q34085125-D1B79A53-03B9-4130-B5FE-A7D2CA7BFE15

P2860

Q34085125-1E62319C-EB8F-4F70-9503-77589A5ABCD1

Q34085125-202811E2-261E-45AC-AA56-5F4CD3D80F4B

Q34085125-4A718DBD-8853-4E66-B5A8-2E6AA2FFE125

Q34085125-4E502D30-A250-4DB4-A6BB-0E2A3323A6E7

Q34085125-66BB066C-BDDE-4917-8688-21DAC982B098

Q34085125-747CDA0F-B24E-47AF-90EE-7D82B363D575

Q34085125-7CB09E38-D332-4F49-975D-1EC51077A096

Q34085125-81C4B3AA-D245-4628-B869-B5A6154C2380

Q34085125-8AB54225-5DB5-48DA-AE01-83F7A0D4A5AC

Q34085125-94690180-08B9-4F5C-81E4-7022E45E3C88

P304

Q34085125-82188BA9-1CB7-4ACD-8612-38A51903D969

P31

Q34085125-F14BB99A-F9A9-4428-901D-F071C0EC3193

P356

Q34085125-00B1AC0E-18EE-49EF-8F2C-68870D2C6D16

P433

Q34085125-847A3DFF-4EBF-4B10-A87B-8F4C6D77EE50

P478

Q34085125-92B738E6-C61A-4E8F-BA45-0F7ED63C56FA

P577

Q34085125-30298B25-CBCE-40A2-B2DF-9D72367DB439

P5875

Q34085125-2C04FAE1-0754-432E-9103-8CE3D075348D

P698

Q34085125-8C61CF24-7D0C-4FF6-9F31-AE4F65CD1D4D

P921

Q34085125-AFA852F0-A8A4-4BCA-A857-38F16B8B30F6

P932

Q34085125-378B6763-65EF-4B67-90FC-E675FB055805

P356

S40261-014-0217-Y

P1433

Clinical Drug Investigation

P1476

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

@en

P2093

Gary A Thompson

http://www.w3.org/2001/XMLSchema#string

Gresel Martinez

http://www.w3.org/2001/XMLSchema#string

Jagadeesh Aluri

http://www.w3.org/2001/XMLSchema#string

Jean Fan

http://www.w3.org/2001/XMLSchema#string

Min Ren

http://www.w3.org/2001/XMLSchema#string

Robert C Shumaker

http://www.w3.org/2001/XMLSchema#string

P2860

Modes of resistance to anti-angiogenic therapy

Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor.

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

Drug interactions between oral contraceptives and antibiotics.

Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase.

The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective.

Pharmacokinetic interactions with rifampicin : clinical relevance.

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

P304

651-659

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40261-014-0217-Y

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263935914

http://www.w3.org/2001/XMLSchema#string

P698

25022720

http://www.w3.org/2001/XMLSchema#string

P921

lenvatinib mesylate

P932

4143598

http://www.w3.org/2001/XMLSchema#string